Journal
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
Volume 108, Issue -, Pages 6-12Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.ijid.2021.05.016
Keywords
Aspirin; Acetylsalicylic acid; Coronavirus; Thrombosis; Outcome
Categories
Ask authors/readers for more resources
This study found that the use of low-dose aspirin is independently associated with reduced mortality in patients with COVID-19. There was also a significant reduction in mortality for patients receiving low-dose aspirin during hospitalization. The included studies had low-to-moderate risk of bias.
Background: This study aimed to investigate whether the active prescription of low-dose aspirin during or prior to hospitalization affects mortality in patients with coronavirus disease 2019 (COVID-19). Aspirin is often prescribed for secondary prevention in patients with cardiovascular disease and other comorbidities that might increase mortality, and may therefore falsely demonstrate increased mortality. To reduce bias, only studies that performed an adjusted analysis were included in this review. Methods: A systematic literature search of PubMed, Scopus, Embase and Clinicaltrials.gov was performed, from inception until 16 April 2021. The exposure was active prescription of low-dose aspirin during or prior to hospitalization. The primary outcome was mortality. The pooled adjusted effect estimate was reported as relative risk (RR). Results: Six eligible studies were included in this meta-analysis, comprising 13,993 patients. The studies had low-to-moderate risk of bias based on the Newcastle-Ottawa Scale. The meta-analysis indicated that the use of low-dose aspirin was independently associated with reduced mortality {RR 0.46 [95% confidence interval (CI) 0.35-0.61], P < 0.001; I-2 = 36.2%}. Subgroup analysis on in-hospital low-dose aspirin administration also showed a significant reduction in mortality [RR 0.39 (95% CI 0.16-0.96), P < 0.001; I-2 = 47.0%]. Conclusion: Use of low-dose aspirin is independently associated with reduced mortality in patients with COVID-19, with low certainty of evidence. (C) 2021 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available